Buying Incyte After the Vega Deal: A Measured Long Trade with Upside and Defense
Incyte's $1.25B acquisition of Vega Therapeutics (06/09/2026) adds a Phase 3 subcutaneous prophylactic for von Willebrand disease that could be a >$1B opportunity. With market cap of roughly $20.6B, FCF of $1.45B and a conservative P/E of 14.4 today, the stock looks primed for re-rating. I move from Hold to Buy with a long-term (180 trading days) t…